O	0	4	Long
O	4	5	-
O	5	9	term
O	10	18	survival
O	19	27	analysis
O	28	30	of
O	31	39	addition
O	40	42	of
B-intervention	43	54	carboplatin
O	55	57	to
O	58	69	neoadjuvant
O	70	82	chemotherapy
O	83	85	in
O	86	90	HER2
O	90	91	-
O	91	99	negative
O	100	106	breast
O	107	113	cancer
O	113	114	.

O	115	123	Addition
O	124	126	of
O	127	138	carboplatin
O	139	140	(
O	140	145	CBDCA
O	145	146	)
O	147	149	to
O	150	161	neoadjuvant
O	162	174	chemotherapy
O	175	176	(
O	176	179	NAC
O	179	180	)
O	181	183	in
O	184	190	triple
O	190	191	-
O	191	199	negative
O	200	206	breast
O	207	213	cancer
O	214	215	(
O	215	219	TNBC
O	219	220	)
O	221	224	has
O	225	233	improved
O	234	246	pathological
O	247	255	complete
O	256	264	response
O	265	266	(
O	266	269	pCR
O	269	270	)
O	271	276	rates
O	277	279	in
O	280	288	previous
O	289	296	studies
O	296	297	.

O	298	300	We
O	301	308	present
O	309	313	long
O	313	314	-
O	314	318	term
O	319	327	survival
O	328	336	outcomes
O	337	338	(
B-outcome-Measure	338	345	disease
I-outcome-Measure	345	346	-
I-outcome-Measure	346	350	free
I-outcome-Measure	351	359	survival
I-outcome-Measure	360	361	[
I-outcome-Measure	361	364	DFS
I-outcome-Measure	364	365	]
O	365	366	,
O	367	370	pre
O	370	371	-
O	371	378	planned
O	379	388	secondary
O	389	397	endpoint
O	397	398	;
B-outcome-Measure	399	406	overall
I-outcome-Measure	407	415	survival
I-outcome-Measure	416	417	[
I-outcome-Measure	417	419	OS
I-outcome-Measure	419	420	]
I-outcome-Measure	420	421	,
O	422	426	post
O	427	430	hoc
O	431	442	exploratory
O	443	451	endpoint
O	451	452	)
O	453	455	of
O	456	459	our
O	460	470	randomized
O	471	476	study
O	477	479	of
O	480	483	the
O	484	492	addition
O	493	495	of
O	496	501	CBDCA
O	502	504	to
O	505	508	NAC
O	509	512	for
O	513	517	HER2
O	517	518	-
O	518	526	negative
O	527	533	breast
O	534	540	cancer
O	540	541	.

B-eligibility	542	550	Patients
I-eligibility	551	555	with
I-eligibility	556	561	stage
I-eligibility	562	564	II
I-eligibility	564	565	/
I-eligibility	565	568	III
I-eligibility	568	569	,
I-eligibility	570	574	HER2
I-eligibility	574	575	-
I-eligibility	575	583	negative
I-eligibility	584	590	breast
I-eligibility	591	597	cancer
O	598	599	(
O	599	600	N
O	601	602	=
B-total-participants	603	606	179
O	606	607	)
O	608	612	were
O	613	621	randomly
O	622	630	assigned
O	631	633	to
O	634	641	receive
O	642	644	CP
O	644	645	-
O	645	648	CEF
O	649	650	(
O	650	654	four
O	655	656	3
O	656	657	-
O	657	661	week
O	662	668	cycles
O	669	671	of
O	672	677	CBDCA
O	678	679	[
O	679	683	area
O	684	689	under
O	690	693	the
O	694	699	curve
O	699	700	,
O	701	702	5
O	703	705	mg
O	705	706	/
O	706	708	mL
O	708	709	/
O	709	712	min
O	712	713	,
O	714	717	day
O	718	719	1
O	719	720	]
O	721	724	and
O	725	731	weekly
O	732	742	paclitaxel
O	743	744	[
O	744	748	wPTX
O	748	749	,
O	750	752	80
O	753	755	mg
O	755	756	/
O	756	758	m2
O	758	759	,
O	760	763	day
O	764	765	1
O	765	766	,
O	767	768	8
O	768	769	,
O	770	772	15
O	772	773	]
O	774	782	followed
O	783	785	by
O	786	790	four
O	791	792	3
O	792	793	-
O	793	797	week
O	798	804	cycles
O	805	807	of
O	808	824	cyclophosphamide
O	824	825	,
O	826	836	epirubicin
O	836	837	,
O	838	841	and
O	842	843	5
O	843	844	-
O	844	856	fluorouracil
O	857	858	[
O	858	861	CEF
O	861	862	,
O	863	866	500
O	866	867	/
O	867	870	100
O	870	871	/
O	871	874	500
O	875	877	mg
O	877	878	/
O	878	880	m2
O	880	881	]
O	881	882	)
O	883	885	or
O	886	887	P
O	887	888	-
O	888	891	CEF
O	892	893	(
O	893	897	four
O	898	904	cycles
O	905	907	of
O	908	912	wPTX
O	913	921	followed
O	922	924	by
O	925	929	four
O	930	936	cycles
O	937	939	of
O	940	943	CEF
O	943	944	)
O	945	947	as
O	948	951	NAC
O	951	952	.

O	953	956	DFS
O	957	960	and
O	961	963	OS
O	964	968	were
O	969	977	analyzed
O	978	980	at
O	981	985	each
O	986	996	population
O	997	999	of
O	1000	1003	pCR
O	1004	1010	status
O	1011	1014	and
O	1015	1023	assigned
O	1024	1033	treatment
O	1034	1037	arm
O	1037	1038	.

O	1039	1041	Of
B-total-participants	1042	1045	179
O	1046	1054	patients
O	1054	1055	,
B-total-participants	1056	1059	154
O	1060	1064	were
O	1065	1074	available
O	1075	1078	for
O	1079	1083	long
O	1083	1084	-
O	1084	1088	term
O	1089	1095	follow
O	1095	1096	-
O	1096	1098	up
O	1098	1099	.

O	1100	1102	At
O	1103	1104	a
O	1105	1111	median
O	1112	1118	follow
O	1118	1119	-
O	1119	1121	up
O	1122	1124	of
O	1125	1126	6
O	1126	1127	.
O	1127	1128	6
O	1129	1134	years
O	1135	1136	(
O	1136	1141	range
O	1141	1142	,
O	1143	1144	0
O	1144	1145	.
O	1145	1146	7
O	1146	1147	-
O	1147	1148	8
O	1148	1149	.
O	1149	1150	0
O	1151	1156	years
O	1156	1157	)
O	1157	1158	,
B-outcome	1159	1167	patients
I-outcome	1168	1171	who
I-outcome	1172	1180	achieved
I-outcome	1181	1184	pCR
O	1185	1186	[
O	1186	1187	n
O	1188	1189	=
O	1190	1192	42
O	1192	1193	,
O	1194	1196	23
O	1196	1197	.
O	1197	1198	5
O	1198	1199	%
O	1200	1201	(
O	1201	1203	CP
O	1203	1204	-
O	1204	1207	CEF
O	1207	1208	:
O	1209	1210	n
O	1211	1212	=
O	1213	1215	28
O	1215	1216	,
O	1217	1218	P
O	1218	1219	-
O	1219	1222	CEF
O	1222	1223	:
O	1224	1225	n
O	1226	1227	=
O	1228	1230	16
O	1230	1231	)
O	1231	1232	]
O	1233	1236	had
O	1237	1243	longer
B-outcome	1244	1247	DFS
I-outcome	1248	1251	and
I-outcome	1252	1254	OS
O	1255	1259	than
O	1260	1263	non
O	1263	1264	-
O	1264	1267	pCR
O	1268	1276	patients
O	1277	1278	[
B-outcome	1278	1281	DFS
O	1281	1282	;
O	1283	1285	HR
O	1286	1287	0
O	1287	1288	.
O	1288	1290	15
O	1291	1292	(
O	1292	1293	0
O	1293	1294	.
O	1294	1296	04
O	1296	1297	-
O	1297	1298	0
O	1298	1299	.
O	1299	1301	61
O	1301	1302	)
O	1302	1303	,
O	1304	1305	P
O	1306	1307	=
O	1308	1309	0
O	1309	1310	.
O	1310	1313	008
O	1313	1314	,
O	1315	1317	OS
O	1317	1318	;
O	1319	1322	log
O	1322	1323	-
O	1323	1327	rank
O	1328	1329	P
O	1330	1331	=
O	1332	1333	0
O	1333	1334	.
O	1334	1337	003
O	1337	1338	]
O	1338	1339	.

O	1340	1348	Addition
O	1349	1351	of
O	1352	1363	carboplatin
O	1364	1366	to
O	1367	1370	NAC
O	1371	1384	significantly
O	1385	1393	improved
B-outcome	1394	1397	DFS
I-outcome	1398	1401	and
I-outcome	1402	1404	OS
I-outcome	1405	1407	in
I-outcome	1408	1411	the
I-outcome	1412	1418	subset
I-outcome	1419	1421	of
I-outcome	1422	1430	patients
I-outcome	1431	1435	with
I-outcome	1436	1440	TNBC
O	1441	1442	[
B-outcome	1442	1445	DFS
O	1445	1446	:
O	1447	1449	HR
O	1449	1450	,
O	1451	1452	0
O	1452	1453	.
O	1453	1455	22
O	1456	1457	(
O	1457	1458	0
O	1458	1459	.
O	1459	1461	06
O	1461	1462	-
O	1462	1463	0
O	1463	1464	.
O	1464	1466	82
O	1466	1467	)
O	1467	1468	,
O	1469	1470	P
O	1471	1472	=
O	1473	1474	0
O	1474	1475	.
O	1475	1478	015
O	1478	1479	;
B-outcome	1480	1482	OS
O	1482	1483	:
O	1484	1486	HR
O	1486	1487	,
O	1488	1489	0
O	1489	1490	.
O	1490	1492	12
O	1493	1494	(
O	1494	1495	0
O	1495	1496	.
O	1496	1498	01
O	1498	1499	-
O	1499	1500	0
O	1500	1501	.
O	1501	1503	96
O	1503	1504	)
O	1504	1505	,
O	1506	1507	P
O	1508	1509	=
O	1510	1511	0
O	1511	1512	.
O	1512	1515	046
O	1515	1516	]
O	1516	1517	,
O	1518	1521	but
O	1522	1525	not
O	1526	1528	in
O	1529	1532	the
B-outcome	1533	1539	subset
I-outcome	1540	1542	of
I-outcome	1543	1551	patients
I-outcome	1552	1556	with
I-outcome	1557	1564	hormone
I-outcome	1565	1573	receptor
I-outcome	1573	1574	-
I-outcome	1574	1582	positive
I-outcome	1583	1590	disease
I-outcome	1591	1593	or
I-outcome	1594	1599	among
I-outcome	1600	1603	all
I-outcome	1604	1612	patients
O	1612	1613	.

O	1614	1622	Addition
O	1623	1625	of
O	1626	1637	carboplatin
O	1638	1640	to
O	1641	1652	neoadjuvant
O	1653	1665	chemotherapy
O	1666	1679	significantly
O	1680	1688	improved
O	1689	1692	DFS
O	1693	1696	and
O	1697	1699	OS
O	1700	1702	in
O	1703	1711	patients
O	1712	1716	with
O	1717	1721	TNBC
O	1722	1725	but
O	1726	1729	not
O	1730	1732	in
O	1733	1738	those
O	1739	1743	with
O	1744	1751	hormone
O	1752	1760	receptor
O	1760	1761	-
O	1761	1769	positive
O	1769	1770	,
O	1771	1775	HER2
O	1775	1776	-
O	1776	1784	negative
O	1785	1791	breast
O	1792	1798	cancer
O	1798	1799	.
